Search the Newsreel

Zacks Research Downgrades Harmony Biosciences (NASDAQ:HRMY) to Hold

Zacks Research has downgraded Harmony Biosciences (NASDAQ:HRMY) from a "strong buy" to a "hold" rating, aligning with the overall consensus. Despite the downgrade, Harmony Biosciences reported a strong quarter with EPS of $1.28 and revenue of $261.28 million, exceeding analyst expectations. The stock opened …

Analysts Offer Insights on NA Companies: Alamar Biosciences, Inc. (ALMR), NIQ Global Intelligence PLC (NIQ) and Amentum Holdings, Inc. (AMTM)

This article summarizes recent analyst ratings for three North American companies: Alamar Biosciences, Inc. (ALMR), NIQ Global Intelligence PLC (NIQ), and Amentum Holdings, Inc. (AMTM). Bank of America Securities reiterated a Hold rating on Alamar Biosciences and a Buy rating on NIQ Global Intelligence, …

Cellectar Biosciences (CLRB) raises $31.7M, flags going concern risk

Cellectar Biosciences 6M 2026: Net loss $(12.6M), Diluted EPS $(1.52) — 10-Q Summary

Cellectar Biosciences reported a consolidated net loss of $(12.6M) and diluted loss per share of $(1.52) for the six months ended June 30, 2026. The company remains pre-revenue but achieved clinical milestones including positive Phase 2 results for CLOVER WaM and FDA Breakthrough Therapy …

Wasatch Advisors LP Sells 175,687 Shares of Castle Biosciences, Inc. $CSTL

Wasatch Advisors LP significantly reduced its stake in Castle Biosciences, Inc. (NASDAQ:CSTL) by selling 175,687 shares, representing a 38.6% decrease, and now holds 279,349 shares valued at approximately $6.66 million. Despite this reduction by Wasatch Advisors, institutional investors collectively own 92.6% of CSTL. The …

Citizens cuts Spruce Biosciences stock price target on share dilution By Investing.com

Citizens has lowered its price target for Spruce Biosciences (NASDAQ:SPRB) from $150.00 to $144.00, citing potential share dilution, while maintaining a Market Outperform rating. Despite the reduction, the new target still indicates significant upside, although InvestingPro data suggests the stock may be overvalued at …

Lionsgate Studios Corp. (NYSE:LION) Receives Average Recommendation of "Moderate Buy" from Analysts

Lionsgate Studios Corp. (NYSE:LION) has received a "Moderate Buy" consensus recommendation from analysts, with an average 12-month price target of $15.575, exceeding its current share price of $11.73. Recent analyst actions include downgrades to "neutral" by Citigroup and Zacks Research, while Barrington Research and …

Is Upgraded Guidance and Data Center Focus Altering The Investment Case For Helios Technologies (HLIO)?

Helios Technologies (HLIO) reported strong Q2 2026 results, raising full-year guidance and completing its business stabilization plan. The company is now entering a "takeoff" phase, targeting data center thermal management as a key growth area. While continued buybacks and dividends add appeal, the stock …

TuHURA Biosciences (HURA) Earnings Date and Reports 2026

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Consensus Rating of "Moderate Buy" by Brokerages

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has received a consensus "Moderate Buy" rating from twenty-four brokerages, with an average 12-month price target of $201.50. The company's stock opened at $156.49, has a market capitalization of $15.91 billion, and has seen significant insider selling totaling over $61 …

Benchmark raises Harvard Bioscience stock price target on revenue beat

Benchmark has increased its price target for Harvard Bioscience (NASDAQ:HBIO) to $7.50 from $6.00, maintaining a Speculative Buy rating after the company surpassed second-quarter revenue guidance. The company reported $22.7 million in revenue, exceeding both management's and consensus estimates, and subsequently raised its full-year …

Lionsgate Studios (LION) Faces Public Pressure To Recast Its Business For AI

Kuros Biosciences AG bestätigt Ergebnisprognose für die Jahre 2026 und 2028

Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Spruce Biosciences announced its second-quarter 2026 financial results and provided updates on its TA-ERT program for MPS IIIB. The company anticipates submitting a Biologics License Application (BLA) in Q4 2026 and initiating the TrAnsform confirmatory study and an Expanded Access Program (EAP) around the …

Navios Maritime Partners (NYSE:NMM) Insider Angeliki Frangou Purchases 1,050 Shares of Stock

Angeliki Frangou, an insider at Navios Maritime Partners (NYSE:NMM), recently purchased an additional 1,050 shares of the company's stock, valued at approximately $83,045. This transaction is part of a series of recent buys, increasing her total holdings to 4.79 million shares. The company has …

Insider Buying: Navios Maritime Partners (NYSE:NMM) Insider Acquires 1,062 Shares of Stock

Angeliki Frangou, an insider at Navios Maritime Partners (NYSE:NMM), recently purchased 1,062 shares of the company's stock for $79.16 per share, increasing her total holdings to over 4.79 million shares. This latest transaction continues a series of insider buys over several trading sessions. The …

Arcus Biosciences (RCUS) Q2 2026 Earnings Call Transcript

Navios Maritime Partners (NMM) CEO adds 3,169 units under 10b5-1 trading plan

Angeliki Frangou, CEO and Chairwoman of Navios Maritime Partners L.P. (NMM), reported purchasing 3,169 common units of NMM between August 10-12, 2026. These open-market purchases were made indirectly through Raymar Investments S.A. under a pre-arranged Rule 10b5-1 trading plan. The purchases occurred at weighted …

Angel Studios Inc (ANGX) (Q2 2026) Earnings Call Highlights: Guild Membership Surges 99% as ...

CuriosityStream Inc. (CURI) stock price, news, quote and history

This article provides detailed financial information for CuriosityStream Inc. (CURI), including its current stock price, recent performance, key financial metrics, analyst ratings, and company overview. It highlights the stock's significant overnight gain, upcoming earnings call, and comparative performance against the S&P 500. The company …

CuriosityStream expects $77M-$82M 2026 revenue while expanding AI training licensing offerings

Earnings Call Insights: CuriosityStream (CURI) Q2 2026 MANAGEMENT VIEW * "Second quarter was a defining quarter for curiosity stream. We delivered the strongest quarterly financial performance in our history, including record operating income, EBITDA, adjusted EBITDA, net income and earnings per share." (President, CEO …

Emergent BioSolutions (EBS) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Wednesday, Aug. 12, 2026 at 5 p.m. ET CALL PARTICIPANTS Vice President and Treasurer - Frank VargoPresident and Chief Executive Officer - Joseph C. Papa Jr.Executive Vice President and Chief Financial Officer - Richard S. Lindahl TAKEAWAYS Total …

Cytek Biosciences (CTKB) awards 241,416 RSUs and 127,118 options to top lawyer

Cytek Biosciences (CTKB) has granted new equity awards to its Chief Legal Officer and Secretary, Ilan Feuchtwang. These awards include 241,416 Restricted Stock Units (RSUs) and an option to purchase 127,118 shares of common stock at an exercise price of $4.66 per share. Both …

Insider Selling: Twist Bioscience (NASDAQ:TWST) CEO Sells $14,182,880.88 in Stock

Twist Bioscience CEO Emily Leproust sold 113,318 shares of company stock for over $14.18 million, reducing her ownership by 12.16%. This sale was executed under a pre-arranged Rule 10b5-1 trading plan, with the stock trading near its one-year high. Despite missing EPS estimates, analysts …

CuriosityStream Inc. (CURI) Tops Q2 Earnings and Revenue Estimates

CuriosityStream Inc. (CURI) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.01 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an …

CuriosityStream (NASDAQ:CURI) Issues Earnings Results, Beats Expectations By $0.11 EPS

Twist Bioscience CEO Emily Leproust Executes Stock Option Exercise and Sells 113,318 Shares Under 10b5-1 Plan

Emily M. Leproust, CEO of Twist Bioscience Corp (NASDAQ:TWST), exercised stock options for 113,318 shares and subsequently sold them for a weighted average price of $125.1615 per share on August 10, 2026. These transactions were executed under a Rule 10b5-1 trading plan established in …

Aura Biosciences (AURA) files Form 3 for Chief People Officer Julie Person

Aura Biosciences, Inc. (AURA) has filed a Form 3, an initial statement of beneficial ownership, for its new Chief People Officer, Julie Person. This filing registers her status as an officer of the company, but it indicates no transactions or current holdings of company …

Forte Biosciences (NASDAQ:FBRX) Releases Earnings Results, Misses Estimates By $0.09 EPS

Forte Biosciences (NASDAQ:FBRX) announced its quarterly earnings, reporting a loss of $0.97 EPS, which missed analysts' consensus estimate of a $0.88 loss by $0.09. The company's shares are trading near their 52-week high, with significant trading volume, and institutional investors holding a large percentage …

Artelo Biosciences (ARTL) trims liabilities, boosts cash amid $5.4M H1 loss

Artelo Biosciences reported a net loss of $5.4 million for the first half of 2026 but significantly improved its liquidity and balance sheet. The company increased cash and cash equivalents to $4.2 million from $0.6 million at year-end 2025 and reduced total liabilities from …

Twist Bioscience (TWST) insider Leproust plans resale after option exercise

Twist Bioscience insider Emily M. Leproust has filed to resell up to 19,952 shares of common stock, valued at over $2.49 million, following a stock option exercise on August 12, 2026. This transaction is detailed in a Form 144 SEC filing, which also indicates …

Forte Biosciences (FBRX) to be acquired by argenx in $77-per-share cash deal

Aura Biosciences (AURA) COO Susan Abu-Absi files initial insider Form 3

Aura Biosciences (AURA) Chief Operating Officer Susan Abu-Absi has filed an initial Statement of Beneficial Ownership (Form 3) with the SEC. This filing establishes her insider status for future reporting but does not report any stock transactions or derivative positions at this time. The …

Aura Biosciences: Ocular Oncology Firm Under New Management Has Shot At Approval

Gufic Biosciences sets Sept 4 AGM; proposes ₹0.10 dividend

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Agios Pharmaceuticals, Inc. (AGIO) and Encourages Shareholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Agios Pharmaceuticals, Inc. (AGIO) following a significant stock drop. The investigation stems from Agios's announcement that its Phase 2 trial for tebapivat in sickle cell disease did not meet the necessary differentiation for continued …